Medicenna Therapeutics (TSX:MDNA) - Cours de l'action, nouvelles et analyse

MDNA Aperçu des actions

Medicenna Therapeutics Corp. est une société d'immunothérapie qui se consacre au développement et à la commercialisation de Superkines et de Superkines renforcées pour le traitement du cancer et d'autres maladies. Plus de détails

MDNA analyse fondamentale
Score flocon de neige
Évaluation	1/6
Croissance future	2/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 72.3% par an

Analyse des risques

Réalise moins d'un million de dollars de revenus ( CA$0 )

Les actionnaires ont été dilués au cours de l'année écoulée

N'a pas de capitalisation boursière significative ( CA$127M )

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

Medicenna Therapeutics Corp. Concurrents

Eupraxia Pharmaceuticals

TSX:EPRX

CA$163.9m

Oncolytics Biotech

TSX:ONC

CA$114.1m

Covalon Technologies

TSXV:COV

CA$109.6m

Satellos Bioscience

TSX:MSCL

CA$86.2m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Medicenna Therapeutics
Historique des cours de bourse
Prix actuel de l'action	CA$1.50
Plus haut sur 52 semaines	CA$2.98
Plus bas sur 52 semaines	CA$0.38
Bêta	1.19
1Variation sur 1 mois	-32.43%
Variation sur 3 mois	-28.91%
Variation sur 1 an	248.84%
3Variation sur 3 ans	-41.41%
Variation sur 5 ans	7.91%
Évolution depuis l'introduction en bourse	-44.44%

Nouvelles et mises à jour récentes

Recent updates

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Oct 18

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Jun 14

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Feb 28

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Nov 08

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

Mar 01

Rendement pour les actionnaires

	MDNA	CA Biotechs	CA Marché
7D	-11.2%	-8.5%	0.7%
1Y	248.8%	1.5%	21.7%

Rendement vs Industrie: MDNA a dépassé le secteur Canadian Biotechs qui a rapporté 1.5 % au cours de l'année écoulée.

Rendement vs marché: MDNA a dépassé le marché Canadian qui a rapporté 21.7 % au cours de l'année écoulée.

Volatilité des prix

Is MDNA's price volatile compared to industry and market?
MDNA volatility
MDNA Average Weekly Movement	11.7%
Biotechs Industry Average Movement	11.7%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.6%
10% least volatile stocks in CA Market	2.9%

Cours de l'action stable: MDNA n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de MDNA ( 12% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
n/a	16	Fahar Merchant	www.medicenna.com

Medicenna Therapeutics Corp. est une société d'immunothérapie qui se consacre au développement et à la commercialisation de superkines et de superkines renforcées pour le traitement du cancer et d'autres maladies. Elle développe bizaxofusp (MDNA55), une interleukine 4 (IL-4) EC pour le traitement du glioblastome récurrent, ainsi que pour les tumeurs cérébrales. L'entreprise développe également le MDNA11, une version améliorée de l'IL-2 pour activer et faire proliférer les cellules immunitaires nécessaires pour combattre le cancer ; le MDNA209, un antagoniste de l'IL-2 pour les maladies auto-immunes, telles que la sclérose en plaques et la maladie du greffon contre l'hôte ; le MDNA413, un double antagoniste de l'IL-4/IL-13 pour traiter les immunothérapies contre le cancer ; le MDNA113, une Superkine anti-PD1-IL2 bifonctionnelle masquée pour diverses tumeurs solides ; et le MDNA132, une Superkine IL-13 pour diverses tumeurs.

Medicenna Therapeutics Corp. Résumé des fondamentaux

Comment les bénéfices et les revenus de Medicenna Therapeutics se comparent-ils à sa capitalisation boursière ?
MDNA statistiques fondamentales
Capitalisation boursière	CA$126.62m
Bénéfices(TTM)	-CA$26.68m
Recettes(TTM)	n/a

0.0x

Ratio P/S

-4.4x

Ratio P/E

Le site MDNA est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
MDNA compte de résultat (TTM)
Recettes	CA$0
Coût des recettes	CA$0
Marge brute	CA$0
Autres dépenses	CA$26.68m
Les revenus	-CA$26.68m

Derniers bénéfices déclarés

Sep 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-0.34
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de MDNA?

Voir les performances historiques et les comparaisons

MDNA Aperçu des actions

Récompenses

Analyse des risques

Medicenna Therapeutics Corp. Concurrents

TSX:EPRX

CA$163.9m

TSX:ONC

CA$114.1m

TSXV:COV

CA$109.6m

TSX:MSCL

CA$86.2m

Historique des prix et performances

Nouvelles et mises à jour récentes

Medicenna Therapeutics Corp. Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (Pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Therapeutics Corp. Presents Preclinical Data from Its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe

Recent updates

Medicenna Therapeutics Corp. Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (Pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Therapeutics Corp. Presents Preclinical Data from Its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe

Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024

Medicenna Therapeutics Files Form 15

Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study

Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting

Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors

Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab

Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp

Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting

Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics Corp.(NasdaqCM:MDNA) dropped from NASDAQ Composite Index

Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer

New major risk - Revenue and earnings growth

Medicenna Therapeutics Corp. Announces Dosing of the First Patient in the Phase 2 Monotherapy Dose Expansion Portion of the Phase 1/2 ABILITY

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer

Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer

Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer

Medicenna Therapeutics Corp. Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp. Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Medicenna Therapeutics Corp., Annual General Meeting, Sep 28, 2023

New minor risk - Share price stability

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023

Price target decreased to CA$7.00

High number of new and inexperienced directors

Medicenna Therapeutics Corp. Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 Ability Study of Mdna11 At the Sitc Annual Meeting

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Price target increased to CA$12.00

Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Lead Independent Director recently bought CA$74k worth of stock

Medicenna Therapeutics Corp. Confirms Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 Ability Study

Medicenna Therapeutics Corp. Presents Preclinical Data Demonstrating Anti-Tumor Activity of Its Anti-Pd1-Il-2 Biskit and Long-Acting Il-4/Il-13 Super-Antagonist At Cytokines 2022

Medicenna Therapeutics Corp. Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. to Report Q1, 2023 Results on Aug 15, 2022

Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp., Annual General Meeting, Sep 21, 2022

No longer forecast to breakeven

Price target decreased to CA$10.63

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11's Favorable Clinical Profile At the 2022 Frontiers in Cancer Immunotherapy Meeting

Medicenna Therapeutics Corp. Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 Ability Study

High number of new and inexperienced directors

Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting

Forecast to breakeven in 2025